- In December 2022, Gilead Sciences, Inc. received approval from the U.S. Food and Drug Administration (FDA) for Sunlenca, to be used alongside other antiretroviral therapies for treating HIV-1 infections in heavily treatment-experienced adults with multi-drug resistant HIV-1. This regulatory approval introduced a novel therapeutic option in the HIV treatment space, enabling the company to expand its existing infectious disease portfolio and strengthen its competitive position
- In May 2022, Eli Lilly received U.S. FDA approval for Mounjaro (tirzepatide) injection, a once-weekly dual GIP and GLP-1 receptor agonist, designed to improve glycemic control in adults with type 2 diabetes. This approval marked a significant advancement in diabetes management, providing patients with an innovative, convenient, and effective treatment option to regulate blood sugar levels and broadening Eli Lilly’s product portfolio
- In February 2021, BioCryst Pharmaceuticals, Inc. secured FDA approval for a supplemental new drug application, expanding eligibility for RAPIVAB, its antiviral treatment for influenza. This approval allowed the company to serve a broader patient population and reinforced its commitment to offering novel antiviral therapies in the infectious disease space
- In July 2021, Novartis announced that branaplam, an oral small molecule, had advanced to Phase 2 clinical trials for the treatment of spinal muscular atrophy (SMA). This milestone marked a crucial development in exploring potential treatments for this severe genetic disorder, highlighting Novartis’s focus on innovation in neurological diseases
- In January 2020, Sanofi S.A. completed the acquisition of Syntrox to enhance its capabilities in developing biotechnological treatments for cancer and autoimmune disorders. This strategic acquisition is expected to accelerate Sanofi’s pipeline expansion and contribute to advancements in therapeutic solutions, thereby supporting growth opportunities within the small molecule sterile injectable drugs market
